Document:

<PAGE>

                                                               EXHIBIT 10.05 (D)

                      AMENDMENT TO STOCKHOLDERS' AGREEMENT
                      ------------------------------------

     AMENDMENT made this 24th day of May, 2001 (the "Amendment"), to that
certain Stockholders' Agreement dated the 6th day of November, 1996, by and
among (i) Occupational Health + Rehabilitation Inc, a Delaware corporation (the
"Company"), (ii) the individuals and entities listed under the heading "Holders"
on Schedule I attached thereto, and (iii) those persons whose names are set
forth under the heading "Investors" on Schedule I thereto (the "Stockholders'
Agreement").  All capitalized terms used herein shall have the meaning assigned
to them in the Stockholders' Agreement unless otherwise defined herein.

     WHEREAS, Prince Venture Partners III Limited Partnership ("Prince"), the
holder of 400,045 shares of Common Stock, wishes to distribute such Common Stock
to its partners (the "Distributees"); and

     WHEREAS, the parties to the Stockholders' Agreement wish to release Prince
and the Distributees from the obligations of the Stockholders' Agreement;

     NOW, THEREFORE, in consideration of the mutual covenants herein contained
and other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the Company, the Holders and the Investors agree as
follows in accordance with paragraph 7 of the Stockholder's Agreement:

     1.  Upon the distribution of the 400,045 shares of Common Stock by Prince
to the Distributees, the Shareholders' Agreement shall be amended (i) to delete
Prince from the list of Holders in Schedule I thereto; (ii) to delete Prince
from the list of OH+R Principal Stockholders; (iii) to delete paragraph 1(b);
and (iv) to delete the list of Telor Principal Stockholders in Schedule II
thereto.  Thereupon, (i) Prince and the Distributees shall be released from all
obligations under the Stockholders' Agreement, including, without limitation,
the obligation to vote shares of Common Stock as specified in the Stockholders'
Agreement; (ii) the Telor Principal Stockholders, other than Prince and the
Distributees, shall be released from their obligations under the Stockholders'
Agreement as Telor Principal Stockholders, including, without limitation, the
obligation to vote their shares of Common Stock as specified in the
Stockholders' Agreement (but they shall not be released from their obligations
under the Stockholders' Agreement arising from their status as Investors); and
(iii) Angus M. Duthie shall continue as a director of the Company until his
successor shall have been duly elected and qualified.

     2.  All other provisions of the Stockholders' Agreement shall remain in
full force and effect in accordance with the terms thereof.

     3.  This Amendment shall become effective upon its execution in accordance
with paragraph 7 of the Stockholders' Agreement.
<PAGE>

     4.  This Amendment may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

     5.  This Amendment shall be construed and enforced in accordance with and
governed by the General Corporation Law of the State of Delaware as to matters
within the scope thereof, and as to all other matters shall be governed by and
construed in accordance with the internal laws of the Commonwealth of
Massachusetts.

     IN WITNESS WHEREOF, the parties hereto have executed this Amendment as a
sealed instrument as of the day and date first above written.

INVESTORS:                                THE COMPANY:
---------                                 -----------

CAHILL, WARNOCK STRATEGIC                 OCCUPATIONAL HEALTH +
PARTNERS FUND, L.P.                       REHABILITATION INC

By:  Cahill, Warnock Strategic
     Partners, L.P.                       By:  /s/ John C. Garbarino
                                               -----------------------

                                          Its:  President and CEO
By:  /s/ Donald W. Hughes
     ----------------------
     Donald W. Hughes
     Its:  General Partner                HOLDERS:
                                          -------

                                          PRINCE VENTURE PARTNERS III
STRATEGIC ASSOCIATES, L.P.                LIMITED PARTNERSHIP

By:  Cahill, Warnock Strategic            By:  Prince Ventures, L.P.
     Partners, L.P.                       Its:  General Partner

By:  /s/ Donald W. Hughes                 By:  /s/ Angus M. Duthie
     ----------------------                    ---------------------
     Donald W. Hughes
     Its:  General Partner                     Its:  General Partner

                                          JOHN C. GARBARINO

                                               /s/ John C. Garbarino
                                               -----------------------

                                       2
<PAGE>

                                 VENROCK ASSOCIATES

                                 By:   /s/ Patrick F. Latterell
                                     --------------------------
                                    Name:   Patrick F. Latterell
                                          ----------------------
                                    Title:   General Partner
                                           -----------------

                                 VENROCK ASSOCIATES II, L.P.

                                 By:   Patrick F. Latterell
                                     ----------------------
                                    Name:   Patrick F. Latterell
                                          ----------------------
                                    Title:   General Partner
                                           -----------------

                                 ASSET MANAGEMENT ASSOCIATES, 1989, L.P.

                                 By:  AMC Partners 89, L.P. General Partner

                                 By:   /s/ Craig C. Taylor
                                     ---------------------

                                    Its:
                                                   GENERAL PARTNER OF
                                     AMC PARTNERS 89, LP. THE GENERAL PARTNER OF
                                          ASSET MANAGEMENT ASSOCIATES 1989, LP.

                                       3<PAGE>

                                                                  Exhibit 10(ff)

                              ORGANOGENESIS INC.
                                 150 Dan Road
                          Canton, Massachusetts 02021

May 15, 2001

Mr. Philip M. Laughlin
135 Benvenue Street
Wellesley, Massachusetts 02482

Dear Phil:

     WHEREAS, you have been employed by Organogenesis Inc./1/ ("Organogenesis"
or the "Company") as its Chief Executive Officer;

     WHEREAS, you are resigning from your position with the Company effective
today;

     WHEREAS, there are potential disputes between you and the Company regarding
your employment by the Company, which both you and the Company wish to resolve;
and

     WHEREAS, you and the Company wish to enter into this letter agreement (the
"Agreement") to confirm the terms regarding your separation of employment with
the Company, including the Company's provision of severance pay and benefits in
exchange for certain agreements by you.

     NOW, THEREFORE, in consideration of the mutual promises and covenants set
forth below and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, you and Organogenesis agree as
follows.

     1.   Separation of Employment.  Your employment with Organogenesis shall
          -------------------------
terminate May 15, 2001 (the "Separation Date"). You acknowledge that from and
after the Separation Date, you shall have no authority and shall not represent
yourself as an officer, employee or agent of Organogenesis, and you expressly
agree that, within two (2) business days from the Separation Date, you shall
resign from all directorships, trusteeships, or other offices currently held by
you with the Company (as that term is defined herein).

     2.   Severance Pay and Benefits.  In exchange for the mutual covenants set
          --------------------------
forth in this Agreement, and commencing on the eighth (8/th/) day following your
execution of this Agreement (the "Effective Date"), the Company agrees to
provide you or, in the event of your death, your estate, with the following
Severance Pay and Benefits:

________________

/1/  For the purposes of this Agreement, the parties agree that the term
Organogenesis Inc. is intended to include Organogenesis, and any other related
entities including any divisions, affiliates, parents and subsidiaries, and its
and their respective officers, directors, employees, agents and assigns.

                                       1
<PAGE>

     (i)    Severance Pay in the amount of Six Hundred Fifty Thousand Dollars
     ($650,000), less all required state, federal and other employment-related
     taxes and deductions, which sum represents two (2) years of base salary and
     which shall be paid to you in twenty-four (24) equal monthly installments
     commencing on June 1, 2001;

     (ii)   a bonus in the amount of Two Hundred Thousand Dollars ($200,000),
     less all required state, federal and other employment-related taxes and
     deductions and which shall be payable to you in twenty-four (24) equal
     monthly installments commencing on March 1, 2002;

     (iii)  Organogenesis will pay you the difference between (a) you and your
     dependants' health and dental insurance premiums paid pursuant to the
     Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") and (b)
     the health and dental insurance premiums you paid while still employed by
     Organogenesis, for a period of one (1) year following the Effective Date of
     this Agreement or until you become eligible for such benefits under a
     subsequent employer's health plan, whichever occurs first (provided,
     however, that such payments are not prohibited by law or by the applicable
     plans);

     (iv)   Organogenesis will pay you the difference between (a) you and your
     dependants' accident and life insurance premiums paid after your
     termination from the Company and (b) the accident and life insurance
     premiums you paid while still employed by Organogenesis, for a period of
     one (1) year following the Effective Date of this Agreement or until you
     become eligible for such benefits under a subsequent employer plans,
     whichever occurs first (provided, however, that such payments are not
     prohibited by law or by the applicable plans);

     (v)    a one time payment equal to the annual cost of a disability policy
     for you and your dependants, provided that such policy provides coverage
     equal to the coverage you and your dependants received while you were
     employed by Organogenesis, with such payment to be made on May 15, 2002;

     (vi)   a fiscal year 2000 bonus of One Hundred and Twenty Thousand Dollars
     ($120,000), to be paid on the Effective Date of this Agreement;

     (vii)  in consideration for the termination of your vested right to
     exercise your option to purchase One Hundred Thousand (100,000) shares of
     Company stock, a lump sum of Seventy Two Thousand Five Hundred Dollars
     ($72,500), said sum representing the value of One Hundred Thousand
     (100,000) shares of Company stock at a price of Seven Dollars and Sixty
     Cents ($7.60) per share less your strike price of Six Dollars and Eighty
                             ----
     Seven and One Half Cents ($6.875) per share, said sum to be paid within One
     Hundred and Twenty (120) days of the Effective Date of this Agreement; and

     (viii) in consideration of the waiver of your right to accelerated
     vesting of the option to purchase Two Hundred Thousand (200,000) shares of
     Company stock pursuant to the Employment Agreement between you and
     Organogenesis dated September 30, 1999, a

                                       2
<PAGE>

     lump sum of One Hundred and Forty Five Thousand Dollars ($145,000), said
     sum representing the value of Two Hundred Thousand (200,000) shares of
     Company Stock at a price of Seven Dollars and Sixty Cents ($7.60) per share

     less your strike price of Six Dollars and Eighty Seven and One Half Cents
     ----
     ($6.875) per share, said sum to be paid within One Hundred and Twenty (120)
     days of the Effective Date of this Agreement.

     You acknowledge and agree that the Severance Pay and Benefits provided
herein are not intended to, and shall not, constitute a severance plan, and
shall confer no benefit on anyone other than the parties hereto and your heirs
and estate. You further acknowledge that except for (i) the specific financial
consideration set forth in this Agreement; (ii) payment of your wages due and
owing for the pay periods up to and including the Separation Date, which shall
be paid to you in accordance with the Company's standard payroll practices; and
(iii) any accrued and unused vacation days that are earned as of the Separation
Date, which the Company paid on the Separation Date, you have been paid and
provided all wages, commissions, bonuses, vacation pay, holiday pay and any
other form of compensation or benefit that may be due to you now or which would
have become due in the future in connection with your employment with or
separation of employment from Organogenesis.

     Regardless of whether or not you execute this Agreement, upon your
termination you may, upon timely completion of the forms required by the COBRA,
continue, at your sole expense, your medical and other insurance coverage to the
extent permitted by COBRA. The COBRA "qualifying event" shall be deemed to be
the Separation Date.

     3.   Confidentiality/Non-Competition/Non-Disparagement.  You expressly
          --------------------------------------------------
acknowledge and agree to the following:

     (i)   that you have returned to Organogenesis all Company property
     (including without limitation, keys, pager, computer, computer equipment,
     computer discs and software, company files and documents, company credit
     cards, etc.) and documents and any copies thereof (including, without
     limitation, financial plans, management reports, development proposals,
     contracts, customer lists, protocols and other similar documents and
     information), regardless of whether they are maintained in hard copy or
     electronic form, except that you may retain the cellular phone that you
     purchased from the Company on May 15, 2001;

     (ii)  that you shall abide by the Non-Competition and Non-Disclosure
     Agreement dated September 30, 1999 that you have previously executed and
     which is attached hereto as Exhibit A (the "Non-Competition Agreement," the
                                 ---------
     terms of which are hereby incorporated by reference and shall survive the
     signing of this Agreement), and that you otherwise shall abide by any and
     all common law and/or statutory obligations relating to protection and non-
     disclosure of Organogenesis' trade secrets and/or confidential and
     proprietary documents and information;

     (iii) that all information relating in any way to this Agreement,
     including the terms and amount of financial consideration provided for in
     this Agreement, shall be held confidential by you and shall not be
     publicized or disclosed to any person (other than an immediate family
     member, legal counsel or financial advisor, provided that any such

                                       3
<PAGE>

     individual to whom disclosure is made agrees to be bound by these
     confidentiality obligations), business entity or government agency (except
     as mandated by state or federal law), and further provided that in the
     event this Agreement or the terms hereof becomes public by operation of law
     or as a result of actions taken or statements made other than by you, this
     Paragraph 3(iii) shall become null and void; and

     (iv)  that, in addition to whatever other remedies may be available to the
     Company in law or in equity, the Company shall recover any Severance Pay
     and Benefits already paid to you pursuant to Section 2 of this Agreement in
     the event you (a) breach any of the covenants set forth in Paragraph 3(ii)
     of this Agreement or (b) fail to resign from, by the Effective Date of this
     Agreement, all directorships, trusteeships, or other offices currently held
     by you with the Company (as that term is defined herein).

Provided, however, that Organogenesis will not assert a claim of breach against
you or withhold payments due you under the terms of this Agreement unless such
action is authorized by resolution of the Organogenesis Board of Directors.
Further, the Company warrants that it presently is aware of no grounds on which
to assert a claim of breach against you.

     4.  Release of Claims. You hereby agree and acknowledge that by signing
this Agreement and accepting the Severance Pay and Benefits, and other good and
valuable consideration provided for in this Agreement, you are waiving your
right to assert any form of legal claim against Organogenesis (as that term is
defined herein) of any kind whatsoever from the beginning of time through the
Effective Date of this Agreement. Your waiver and release herein is intended to
bar any form of legal claim, charge, complaint or any other form of action
(jointly referred to as "Claims") against the Company seeking any form of relief
including, without limitation, equitable relief (whether declaratory, injunctive
or otherwise), the recovery of any damages or any other form of monetary
recovery whatsoever (including, without limitation, back pay, front pay,
compensatory damages, emotional distress damages, punitive damages, attorneys
fees and any other costs) against it up through the Effective Date of this
Agreement.

     Without limiting the foregoing general waiver and release, you specifically
waive and release Organogenesis from any Claim arising from or related to your
employment relationship with Organogenesis or the termination thereof through
the Effective Date of this Agreement, including, without limitation:

     **   Claims under any state or federal discrimination, fair employment
          practices or other employment related statute, regulation or executive
          order (as they may have been amended through the Effective Date)
          prohibiting discrimination or harassment based upon any protected
          status including, without limitation, race, national origin, age,
          gender, marital status, disability, veteran status or sexual
          orientation.  Without limitation, specifically included in this
          paragraph are any Claims arising under the federal Age Discrimination
          in Employment Act, the Older Workers Benefit Protection Act, the Civil
          Rights Acts of 1866 and 1871, Title VII of the Civil Rights Act of
          1964, the Civil Rights Act of 1991, the Equal Pay Act, the Americans
          With Disabilities Act and any similar Massachusetts, or other state
          statute.

                                       4
<PAGE>

     **   Claims under any other state or federal employment related statute,
          regulation or executive order (as they may have been amended through
          the Effective Date) relating to wages, hours or any other terms and
          conditions of employment.  Without limitation, specifically included
          in this paragraph are any Claims arising under the Fair Labor
          Standards Act, the Family and Medical Leave Act of 1993, the National
          Labor Relations Act, the Employee Retirement Income Security Act of
          1974, the Consolidated Omnibus Budget Reconciliation Act of 1985
          (COBRA) and any similar Massachusetts, or other state statute.

     **   Claims under any state or federal common law theory including, without
          limitation, wrongful discharge, breach of express or implied contract,
          promissory estoppel, unjust enrichment, breach of a covenant of good
          faith and fair dealing, violation of public policy, defamation,
          interference with contractual relations, intentional or negligent
          infliction of emotional distress, invasion of privacy,
          misrepresentation, deceit, fraud or negligence.

     **   Any other Claim arising under state or federal law.

     Notwithstanding the foregoing, this Section shall not release Organogenesis
from (i) non-termination related workers' compensation claims and claims arising
under disability insurance policies; (ii) claims to vested account balances in
any 401(k) benefit plans; or (iii) any obligation expressly set forth in, or
rights to enforce, this Agreement.  Further, nothing in this release shall
operate as a release or waiver by you of any rights to defense and/or
indemnification under any (i) indemnification agreement to which the Company
(including any subsidiary or parent) is a party; (ii) applicable law; (iii)
certificates of incorporation and/or bylaws of Organogenesis (including any
subsidiary or parent); or (iv) Directors' and Officers' Liability Policy, which
policy or equivalent coverage Organogenesis shall maintain on your behalf at the
level in effect immediately prior to the Separation Date throughout the period
of any applicable statute of limitations.  You acknowledge and agree that, but
for providing this release of claims, you would not be receiving the Severance
Pay and Benefits being provided to you under the terms of this Agreement.

     You explicitly acknowledge that because you are over forty (40) years of
age, you have specific rights under the Age Discrimination in Employment Act and
the Older Workers Benefits Protection Act ("OWBPA"), which prohibit
discrimination on the basis of age, and that the releases set forth in this
section are intended to release any right that you may have to file a claim
against Organogenesis alleging discrimination on the basis of age.

     Consistent with the provisions of the OWBPA, Organogenesis is providing you
with twenty-one (21) days (until June 4, 2001) in which to consider and accept
the terms of this Agreement by signing below and returning it to John Arcari,
Organogenesis Inc., 150 Dan Road, Canton, Massachusetts 02021.  Of course, you
may choose to sign and return this Agreement sooner than June 4, 2001 if you
wish. In addition, you may rescind your assent to this Agreement if, within
seven (7) days after you sign this Agreement, you deliver a notice of rescission
to John Arcari.  To be effective, such rescission must be hand delivered or
postmarked within the seven (7) day period and sent by certified mail, return
receipt requested, to John Arcari, Organogenesis Inc., 150 Dan Road, Canton,
Massachusetts 02021.

                                       5
<PAGE>

     5.  Entire Agreement/Choice of Law/Enforceability. You acknowledge and
         ----------------------------------------------
agree that with the exception of the Non-Competition Agreement, this Agreement
supersedes any and all prior or contemporaneous oral and/or written agreements
between you and the Company, and sets forth the entire agreement between you and
the Company. You specifically acknowledge and agree that this Agreement
supersedes the Employment Agreement between you and Organogenesis dated
September 30, 1999, which agreement, as of the Effective Date, shall have no
force or effect. No variations or modifications hereof shall be deemed valid
unless reduced to writing and signed by the parties hereto.

     This Agreement shall be deemed to have been made in the Commonwealth of
Massachusetts, shall take effect as an instrument under seal within
Massachusetts, and the validity, interpretation and performance of this
Agreement shall be governed by, and construed in accordance with, the internal
law of the Commonwealth of Massachusetts, without giving effect to conflict of
law principles. Both parties further acknowledge that the last act necessary to
render this Agreement enforceable is its execution by Organogenesis in
Massachusetts, and that the Agreement thereafter shall be maintained in
Massachusetts. Both parties agree that any action, demand, claim or counterclaim
relating to the terms and provisions of this Agreement, or to its breach, shall
be commenced in Massachusetts in a court of competent jurisdiction. Both parties
further acknowledge that venue shall lie exclusively in Massachusetts. Both
parties further agree that any action, demand, claim or counterclaim shall be
resolved by a judge alone, and both parties hereby waive and forever renounce
the right to a trial before a civil jury. The provisions of this Agreement are
severable, and if for any reason any part hereof shall be found to be
unenforceable, the remaining provisions shall be enforced in full.

     By executing this Agreement, you are acknowledging that you have been
afforded sufficient time to understand the terms and effects of this Agreement,
that your agreements and obligations hereunder are made voluntarily, knowingly
and without duress, and that neither Organogenesis nor its agents or
representatives have made any representations inconsistent with the provisions
of this Agreement.

     6.   Confirming Authority.  Organogenesis hereby represents that the Board
          --------------------
of Directors has authorized and directed John Arcari, Vice President for Finance
and Administration and Chief Financial Officer, to enter into this Agreement on
behalf of the Company and to bind the Company to the terms and conditions
hereof.

                                       6
<PAGE>

     If the foregoing correctly sets forth our understanding, please sign, date
and return the enclosed copy of this Agreement to John Arcari within the time
frame set forth above.

                                    Very truly yours,

                                    ORGANOGENESIS INC.

                                    By: /s/ John Acari
                                         ___________________
                                         John Arcari
                                         Vice President, Finance &
                                         Administration and
                                         Chief Financial Officer

Confirmed and Agreed:

/s/ Philip M. Laughlin
________________________
Philip M. Laughlin

Dated: _______________________

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]